<DOC>
	<DOCNO>NCT00003211</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy radiation therapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy radiation therapy kill tumor cell . PURPOSE : Phase II trial study effectiveness chemotherapy topotecan , cyclophosphamide , cisplatin , vincristine plus radiation therapy peripheral stem cell transplantation treat child newly diagnose medulloblastoma supratentorial primitive neuroectodermal tumor .</brief_summary>
	<brief_title>Chemotherapy , Radiation Therapy , Peripheral Stem Cell Transplantation Treating Children With Newly Diagnosed Medulloblastoma Supratentorial Primitive Neuroectodermal Tumor</brief_title>
	<detailed_description>OBJECTIVES : - Estimate response rate topotecan child newly diagnose medulloblastoma supratentorial primitive neuroectodermal tumor measurable residual disease surgery . ( Topotecan window close accrual 9/10/2001 ) - Determine feasibility four course high-dose chemotherapy ( vincristine , cisplatin , cyclophosphamide ) peripheral blood stem cell support craniospinal irradiation ( CSI ) patient . - Estimate 5-year overall survival progression-free survival patient treat risk-adapted CSI high-dose chemotherapy . - Compare change intellectual functioning patient treat reduced-dose vs standard-dose CSI . - Estimate incidence ototoxicity associate risk-adapted CSI posterior fossa boost ( ) give 3-D conformal radiotherapy technique combine amifostine cisplatin . OUTLINE : This multicenter study . Patients assign 1 2 treatment group base risk status . - Group 1 ( average-risk ) : Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) IV daily peripheral blood stem cell ( PBSC ) harvest . PBSC harvest blood count recover . Patients receive craniospinal irradiation ( CSI ) 5 day week 6 week . Beginning 6 week completion CSI , patient receive high-dose chemotherapy comprise vincristine IV follow cisplatin IV 6 hour day -4 cyclophosphamide IV 1 hour day -3 -2 . Patients receive amifostine IV 1 minute maximum 5 minute prior cisplatin infusion 3 hour cisplatin infusion . PBSC reinfused day 0 . Patients receive G-CSF SC begin day 1 continue minimum 7 day blood count recover . Vincristine IV administer day 6 . G-CSF stop 48 hour prior begin subsequent course chemotherapy . High-dose chemotherapy repeat every 4 week 4 course . - Group 2 ( high-risk ) : Patients receive topotecan IV 4 hour day 1-5 G-CSF SC IV begin 24 hour completion first course topotecan continue PBSC harvest . Treatment repeat every 3 week 2 course . If adequate number PBSC harvest , patient undergoes second harvest PBSC second course topotecan . Patients receive CSI , high-dose chemotherapy , amifostine , PBSC support group 1 . ( Topotecan window close accrual 9/10/2001 ) Patients undergo neuropsychological test prior radiotherapy chemotherapy 1 , 2 , 5 year . Patients follow 1 , 2 , 4 , 6 , 9 , 12 , 15 , 18 , 24 month every 6 month 3 year . PROJECTED ACCRUAL : A total 12-36 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven medulloblastoma supratentorial primitive neuroectodermal tumor Averagerisk group : Localized tumor overt evidence invasion beyond posterior fossa Less 1.5 cm2 residual tumor/imaging abnormality No CNS extraneural metastasis ( confirm bone scan ) Brain stem invasion allow criterion meet Highrisk group : Metastatic disease within neuraxis ( subarachnoid dissemination ) OR great 1.5 cm^2 residual disease primary site surgery No bone involvement bone scan Must begin study within 28 day definitive surgery PATIENT CHARACTERISTICS : Age 3 20 diagnosis Performance status ECOG 03 ( except patient posterior fossa syndrome ) Life expectancy Not specify Hematopoietic WBC great 3,000/mm^3 Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 10 g/dL Hepatic Bilirubin le 1.5 mg/dL SGPT le 1.5 time normal Renal Creatinine le 1.2 mg/dL OR Creatinine clearance great 70 mL/min Other Not pregnant nursing Negative pregnancy test HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Prior corticosteroid allow Radiotherapy No prior radiotherapy Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>untreated childhood medulloblastoma</keyword>
</DOC>